On July 3, Jiangxi Biologics rose 9.52% in regular trading, trading at HKD 6.82/share, with turnover of HKD 1.8971 million.

On the news front, the company announced that its wholly-owned subsidiary Chifeng Born Pharmaceutical Co., Ltd. has successfully obtained the Veterinary Drug Product Approval Number Certificate for its veterinary tetanus antitoxin product, which is primarily used for the prevention and treatment of tetanus infection in animals. The market had previously expressed concern over the company's heavy reliance on a single product — human tetanus antitoxin (TAT), which accounts for over 96% of revenue. This veterinary product approval is expected to improve the company's product diversification and open up the animal health market segment.

Jiangxi Biologics listed on the Hong Kong Stock Exchange on June 30 at an IPO price of HKD 11.2, but broke below its offering price on the first day and continued to decline thereafter. The release of this positive development has triggered a notable rebound in the share price.

Jiangxi Biologics is a national high-tech enterprise in the antitoxin and immune serum biopharmaceutical sector, and is China's and the world's largest provider of human tetanus antitoxin with a 65.8% domestic market share. Its products are exported to over 30 countries and regions.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)